Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura

Hematology

Volumn 9, Issue 4, 2004, Pages 287-289

  Lalayanni, Chrisavgi ^a   Stavroyianni, Niki ^a   Saloum, Riad ^a   Tsompanakou, Aliki ^a   Anagnostopoulos, Achilles ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Cytotoxicity; Refractory immune thrombocytopenia; Rituximab; Side effects

Indexed keywords

ASCORBIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

AGED; ARTICLE; CASE REPORT; CHRONIC DISEASE; DEATH; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LIVER ABSCESS; LUNG EMBOLISM; LYMPHOCYTOPENIA; NEUTROPENIA; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; REMISSION; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; FEMALE; HUMANS; LIVER ABSCESS; MALE; MIDDLE AGED; PNEUMONIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION;

EID: 5444225387     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/10245330410001714248     Document Type: Article

References (10)

1. Provan, D. and Newland, A. (2002) "Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Review", Br. J. Haematol. 118, 933-944.
2. George, J., Woolf, S., Raskob, G., Wasser, J., Aledort, L., Ballem, P., Blanchette, V., Bussel, J., Cines, D., Kelton, J., Lichtin, A., McMilan, R., Okerbloom, J., Regan, D. and Warrier, I. (1996) "Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology", Blood 88, 3-40.
3. Zaja, F., Iacoma, I., Masolini, P., Russo, D., Sperotto, A., Prosdocimo, S., Patriarca, F., Vita, S., Regazzi, M., Baccarani, M. and Fanin, R. (2002) " B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia", Haematologica 87, 189-195.
4. Berentsen, S., Tjønnfjord, G., Brudevold, R., Gjertsen, B., Langholm, R., Løkkevik, E., Søbrø, J.H. and Ulvestad, E. (2001) "Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease", Br. J. Haematol. 115, 79-83.
5. Hassan, G. (2002) "Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia", Blood 99, 1092-1094.
6. Reff, M.E., Carner, K., Chambers, K.S., Chinn, C., Leonard, J. and Raab, R. (1994) "Depletion of B cell in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood 83, 435-445.
7. Stasi, R., Pagano, A., Stipa, E. and Amadori, S. (2001) "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura", Blood 98, 952-957.
8. Delgado, J., Bustos, J., Jimenez-Yuste, V. and Hernandez-Navarro, F. (2002) "Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura", Haematologica 87 215-216.
9. Stasi, R., Stipa, E., Forte, V, Meo, P. and Amadori, S. (2002) "Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura", Blood 99, 3872-3873.
10. Heelan, B., Tormey, V., Amlot, P., Payne, E., Mehta, A. and Webster, D. (2002) "Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome", Br. J. Haematol. 118, 1078-1081.